Law firm looking into whether BioMimetic was shopped enough

Delaware-based law firm Rigrodsky & Long says it is investigating the planned sale of BioMimetic Therapeutics to Wright Medical Group — which could grow in value to $380 million — to see if BioMimetic's board marketed the company appropriately and got the best buyout price. On his team's conference call this morning, Wright Medical CEO Bob Palmisano said his team had been following BioMimetic for years and added that, "I assume lots of other companies have looked as well."